extracellular exosome

Overview

Extracellular exosomes are small extracellular vesicles released by cells into the extracellular space and found in many body fluids, including human plasma, urine, and nipple discharge. They carry membrane proteins, lipids, and nucleic acids that reflect the molecular state of their parent cells, making them important mediators of intercellular communication and attractive candidates for biomarker discovery, drug delivery, and therapeutic engineering. In biomedical research, exosomes are often discussed together with broader extracellular vesicle populations, but the term specifically refers to a nanoscale vesicular subtype with a defined biogenesis pathway.

From a therapeutic and translational perspective, exosomes are being investigated both as natural delivery vehicles and as disease-associated analytes. Their membrane composition and cargo can be exploited for targeted delivery of drugs, nucleic acids, or genome-editing systems, while their endogenous origin may offer advantages over synthetic carriers. At the same time, their abundance and molecular signatures are being studied for noninvasive sensing strategies in cancer and other diseases, including breast cancer, bladder cancer, and neurological and inflammatory disorders.

Focus of Latest Publications

Recent studies have used extracellular exosomes as both a therapeutic platform and a diagnostic target. In rheumatoid arthritis research, mesenchymal stem cell-derived extracellular vesicles were investigated for their ability to alleviate disease progression in collagen-induced arthritis by modulating autophagy in fibroblast-like synoviocytes. The reported mechanism involved USP21-dependent BRD2 stabilization, highlighting how extracellular vesicle cargo can influence intracellular signaling pathways relevant to inflammatory disease. The publication also emphasized a practical limitation of EVs-MSC: their natural low targeting specificity and insufficient bioactive cargo, which may reduce clinical efficacy.

In cancer diagnostics, exosomes were repeatedly positioned as liquid biopsy targets because they reflect the molecular profile of their parent cells. One study developed a multiplexed peptide-based fluorescent probe platform for analysis of HER2-positive exosomal membrane proteins, using HER2-binding Peptides to interrogate exosomal surface markers. Another study focused on bladder cancer biomarker discovery by high-throughput screening of exosome biomarkers with barcodes integrated herringbone microfluidics, aiming for efficient exosome enrichment and multiplexed biomarker detection. These approaches support the use of exosomes in point-of-care cancer diagnostics and noninvasive sensing strategies.

breast cancer screening was also explored through extracellular vesicles in nipple discharge, where cellulose nanofiber sheets were used to identify EV-associated miRNAs as candidate clinical biomarkers. This work extended the diagnostic utility of exosomes to a minimally invasive sample source. Related exosome-based biomarker concepts were also discussed in the context of HER2-positive disease, reinforcing the role of exosomal membrane proteins as accessible analytes for liquid biopsy.

Exosomes were additionally discussed as delivery vehicles in therapeutic engineering. A study on ssDNA modification of lipid carriers described liposomes and exosomes as nanoscale vesicular structures composed of phospholipids, glycolipids, membrane proteins, and cholesterol, and noted their broad investigation as drug- and nucleic-acid-delivery systems. This aligns with broader work on non-viral delivery approaches, where exosomes were listed alongside lipid nanoparticles, gold nanoparticles, and stimuli-responsive systems such as MMP-cleavable nanoparticles and hypoxia-responsive nanoparticles. In the context of CRISPR-based gene editing and programmable genome engineering, exosomes were highlighted as a potential carrier for delivering editing components, including in efforts related to APOE4 correction in Alzheimer’s disease. The same translational discussion noted persistent barriers such as limited delivery efficiency across the blood-brain barrier, allele specificity, and genomic safety concerns.

Exosomes also appeared in broader reviews of regenerative and senotherapeutic approaches. In diabetic kidney disease, mesenchymal stem/stromal cells and their derived extracellular vesicles were identified among commonly studied cellular therapies, indicating ongoing interest in exosome-mediated tissue repair and anti-senescent effects. Across these studies, exosomes were treated as biologically active vesicles with both diagnostic value and therapeutic promise, but with important challenges in targeting, cargo loading, and clinical translation.

Key Publications

• NEWJun Aging impact on canine extracellular vesicles production, size, and miRNA content. (Veterinary research communications, 2026, PMID 42319614): "Extracellular vesicles (EVs) are lipid-bilayer vesicles that mediate intercellular communication by transporting proteins, lipids, and regulatory RNAs, including microRNAs (miRNAs)."
• NEWJun EcN-Sj16-Exo ameliorates experimental asthma by inhibiting eosinophil extracellular trap formation via N-WASP upregulation. (The European respiratory journal, 2026, PMID 41713945): "Exosomes, with their protective phospholipid bilayer, serve as efficient drug carriers."
• NEWJun Identification and multi-omics analysis of extracellular vesicles from the plerocercoids of Spirometra mansoni (Cestoda: Diphyllobothriidae). (Parasitology research, 2026, PMID 42310140): "Parasitic extracellular vesicles (EVs) play crucial roles in the growth and development of parasites."
• Jun EVs-MSC alleviate RA progression via USP21-dependent BRD2 stabilization to regulate autophagy in FLS. (Biochemical pharmacology, 2026, PMID 42302977): "While mesenchymal stem cell-derived extracellular vesicles (EVs-MSC) show therapeutic potential, their natural limitations-such as low targeting specificity and insufficient bioactive cargo-hinder clinical efficacy."
• Jun Extracellular vesicles in nipple discharge for breast cancer screening. (Breast cancer research and treatment, 2026, PMID 42307695): "This study aimed to identify extracellular vesicles (EVs) miRNAs in ND using cellulose nanofiber (CNF) sheets to develop clinical biomarkers."
• Jun ssDNA Modification on Lipid Carriers Utilizing ssDNA-Conjugated Fusion Protein with Cholesterol-Binding Ability. (Bioconjugate chemistry, 2026, PMID 42231670): "Lipid carriers, such as liposomes and exosomes, are nanoscale vesicular structures composed of phospholipids, glycolipids, membrane proteins, and cholesterol, which have been widely investigated as drug- and nucleic-acid-delivery systems."
• Jun Multiplexed Peptide-Based Fluorescent Probe Platform for Analysis of HER2-Positive Exosomal Membrane Proteins. (Analytical chemistry, 2026, PMID 42215863): "Exosomes, nanoscale vesicles reflecting the molecular profiles of their parent cells, offer a promising liquid biopsy approach."
• Jun High-throughput screening of bladder cancer exosome biomarkers by barcodes integrated herringbone microfluidics. (Biosensors & bioelectronics, 2026, PMID 41740420): "...for efficient exosome enrichment and multiplexed biomarker detection."
• Apr CRISPR-mediated cancer therapies: Approaches to direct tumor targeting. (Critical reviews in oncology/hematology, 2026, PMID 41833894): "Non-viral approaches include lipid nanoparticles, gold nanoparticles, exosomes, and stimuli-responsive systems such as MMP-cleavable and hypoxia-responsive nanoparticles."
• Apr Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches. (Kidney international, 2026, PMID 41581730): "Commonly studied cellular therapies in DKD include mesenchymal stem/stromal cells and their derived extracellular vesicles."